On Thursday, Intellia Therapeutics Inc (NASDAQ: NTLA ) outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z .

These therapies target hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis, respectively.

Intellia prioritized NTLA-2002 and nex-z while discontinuing the NTLA-3001 program and other early-stage initiatives.

The reorganization will result in a 27% workforce reduction and a projected $8 million restructuring charge in early 2025.

Intellia ended the fourth quarter of 2024 with approximately $862 million in cash, cash equivalents and investments.

Intellia ended 2024 with $862 million in cash and investments, projecting a cash runway through the first half of 2027, bolstered by anticipated cost savings from its reorganization.

Pipeline Progress and Financial Standing

2025 Milestones and Commercial Plans

Price Action: NTLA stock is down 12.7% at $10.49 at last check Friday.

Read Next:

Image via Shutterstock.

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?

This article Why Is Intellia Therapeutics Stock Trading Lower On Friday? originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.